Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Veru
(NASDAQ:VERU)
Intraday
$1.28
0.07
[5.79%]
After-Hours
$1.28
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$1.28
0.07
[5.79%]
At close: Apr 26
$1.28
0
[0.00%]
After Hours: 7:08PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Veru Stock (NASDAQ:VERU)
Veru Stock (NASDAQ: VERU)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, April 15, 2024
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Avi Kapoor
-
Apr 15, 2024, 2:11PM
Cisco To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Monday
Avi Kapoor
-
Apr 15, 2024, 8:39AM
Oppenheimer Reiterates Outperform on Veru, Lowers Price Target to $5
Benzinga Newsdesk
-
Apr 15, 2024, 7:55AM
Friday, April 12, 2024
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Avi Kapoor
-
Apr 12, 2024, 2:47PM
Tuesday, April 09, 2024
12 Consumer Staples Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
-
Apr 9, 2024, 4:31PM
Thursday, March 28, 2024
Veru shares are trading higher after Raymond James initiated coverage on the stock with an Outperform rating and a price target of $3.
Benzinga Newsdesk
-
Mar 28, 2024, 7:18AM
Raymond James Initiates Coverage On Veru with Outperform Rating, Announces Price Target of $3
Benzinga Newsdesk
-
Mar 28, 2024, 6:10AM
Wednesday, March 27, 2024
Watching Veru; Traders Circulate Analyst Comments Suggesting Co Could See A Take Out From Large Pharma Due To Effectivr GLP-1; Gives It An Outperform Rating And $3 PT
Benzinga Newsdesk
-
Mar 27, 2024, 4:14PM
Wednesday, February 28, 2024
Reported Earlier, Veru Receives Nasdaq Notice For Delay In Filing Quarterly Report
Benzinga Newsdesk
-
Feb 28, 2024, 2:22AM
Thursday, February 08, 2024
HC Wainwright & Co. Reiterates Buy on Veru, Maintains $2 Price Target
Benzinga Newsdesk
-
Feb 8, 2024, 3:25PM
Veru Q1 Sales $2.10M Miss $5.20M Estimate
Benzinga Newsdesk
-
Feb 8, 2024, 6:32AM
Earnings Scheduled For February 8, 2024
Benzinga Insights
-
Feb 8, 2024, 4:43AM
Tuesday, February 06, 2024
8 Consumer Staples Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Feb 6, 2024, 12:31PM
Veru Announces FDA Clearance Of IND Application For Phase 2b Clinical Trial With Enobosarm To Treat Muscle Loss Associated With Weight Loss Drugs
Benzinga Newsdesk
-
Feb 6, 2024, 8:31AM
Monday, January 08, 2024
Veru Submits IND Application To FDA For Development Of Enobosarm To Prevent Muscle Loss While Augmenting Fat Loss In Combination With GLP-1 Drugs For Weight Loss
Benzinga Newsdesk
-
Jan 8, 2024, 8:38AM
Tuesday, December 26, 2023
Veru Inc. 13G Filing Shows Adage Capital Partners, L.P. Reported A 9.5% Stake In The Co As Of December 14, 2023
Benzinga Newsdesk
-
Dec 26, 2023, 4:40PM
Tuesday, December 19, 2023
Veru To Host Investor Call On January 4th, 2024 To Discuss Recent Financing And Strategy To Prioritize The Development Of Enobosarm As A Combination Treatment To Prevent Muscle Loss And Augment Fat Loss Associated With Weight Loss GLP-1 Drugs
Benzinga Newsdesk
-
Dec 19, 2023, 8:42AM
Thursday, December 14, 2023
Veru Announced Today The Pricing Of An ~$33M Underwritten Public Offering Of 45,833,333 Shares Of Its Common Stock At A Price To The Public Of $0.72/Share
Benzinga Newsdesk
-
Dec 14, 2023, 9:05AM
Wednesday, December 13, 2023
Veru Commences Public Offering Of Shares Of Its Common Stock; No Terms Disclosed
Benzinga Newsdesk
-
Dec 13, 2023, 4:03PM
Monday, December 11, 2023
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
Avi Kapoor
-
Dec 11, 2023, 1:12PM
Wednesday, October 04, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Oct 4, 2023, 12:01PM
Veru To Advance Enobosarm Into A Phase 2b Clinical Trial In Combination With Weight Loss GLP-1 Drugs Ozempic, Wegovy Or Mounjaro To Evaluate Efficacy And Safety Of Enobosarm To Further Increase Fat Loss While Preventing Muscle Wasting
Bill Haddad
-
Oct 4, 2023, 8:33AM
Monday, October 02, 2023
Visionary Education Technology Holdings Group Inc. Will Be Changing Its Ticker Symbol From "VEDU" To "GV". Effective When The Market Opens On Monday, October 9, 2023
Benzinga Newsdesk
-
Oct 2, 2023, 4:01PM
Friday, September 29, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Sep 29, 2023, 2:09PM
Wednesday, September 27, 2023
HC Wainwright & Co. Reiterates Buy on Veru, Maintains $2 Price Target
Benzinga Newsdesk
-
Sep 27, 2023, 6:50AM
Tuesday, September 26, 2023
11 Consumer Staples Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
-
Sep 26, 2023, 9:06AM
Veru Reaches Agreement With FDA On New Phase 3 Clinical Trial For Sabizabulin For Broader Indication: Hospitalized Adult Patients With Any Type Of Viral Acute Respiratory Distress Syndrome
Benzinga Newsdesk
-
Sep 26, 2023, 8:34AM
Tuesday, September 19, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Sep 19, 2023, 12:50PM
Monday, September 11, 2023
Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer
Benzinga Newsdesk
-
Sep 11, 2023, 7:02AM
Thursday, August 10, 2023
Earnings Scheduled For August 10, 2023
Benzinga Insights
-
Aug 10, 2023, 6:59AM
Veru Q3 EPS $0.07 Beats $(0.20) Estimate, Sales $3.34M Miss $10.22M Estimate
Benzinga Newsdesk
-
Aug 10, 2023, 6:31AM
Thursday, July 20, 2023
9 Consumer Staples Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
-
Jul 20, 2023, 9:06AM
Wednesday, June 07, 2023
6 Analysts Have This to Say About Veru
Benzinga Insights
-
Jun 7, 2023, 3:01PM
Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2023
Benzinga Insights
-
Jun 7, 2023, 11:00AM
What 6 Analyst Ratings Have To Say About Veru
Benzinga Insights
-
Jun 7, 2023, 8:09AM
Jefferies Upgrades Veru to Hold, Announces $1 Price Target
Benzinga Newsdesk
-
Jun 7, 2023, 5:18AM
Friday, May 19, 2023
Veru Says Clinical Trial Of VERU-100 To Determine An Effective Dose Of VERU-100 For The Treatment Of Advanced Prostate Cancer Has Been Terminated As Endpoints Were Not Achieved At Current Dose Level
Benzinga Newsdesk
-
May 19, 2023, 11:42AM
Tuesday, May 16, 2023
Veru Has Been Granted U.S. Patent Number 11,648,236 Titled "Methods Of Treating Coronavirus"
Happy Mohamed
-
May 16, 2023, 11:16AM
Monday, May 15, 2023
HC Wainwright & Co. Maintains Buy on Veru, Lowers Price Target to $2
Benzinga Newsdesk
-
May 15, 2023, 6:51AM
Thursday, May 11, 2023
Veru shares are trading lower after the company reported worse-than-expected Q2 EPS results.
Benzinga Newsdesk
-
May 11, 2023, 1:00PM
Veru Q2: Revenue Halves, Prioritizes Clinical Programs, Wider Loss & More
Nabaparna Bhattacharya
-
May 11, 2023, 10:58AM
Earnings Scheduled For May 11, 2023
Benzinga Insights
-
May 11, 2023, 9:58AM
Veru: Q2 Earnings Insights
Benzinga Insights
-
May 11, 2023, 6:40AM
Veru Q2 EPS $(0.48) Misses $(0.33) Estimate, Sales $6.59M Beat $4.32M Estimate
Benzinga Newsdesk
-
May 11, 2023, 6:32AM
Wednesday, May 10, 2023
A Preview Of Veru's Earnings
Benzinga Insights
-
May 10, 2023, 1:03PM
Monday, May 08, 2023
Analyst Ratings for Veru
Benzinga Insights
-
May 8, 2023, 1:01PM
HC Wainwright & Co. Reiterates Buy on Veru, Maintains $6 Price Target
Benzinga Newsdesk
-
May 8, 2023, 6:23AM
Thursday, May 04, 2023
Veru Reaches Agreement With FDA On Confirmatory Phase 3 Clinical Trial For Sabizabulin Treatment Of Hospitalized COVID-19 Adult Patients At High Risk For ARDS
Happy Mohamed
-
May 4, 2023, 8:31AM
Wednesday, May 03, 2023
Veru Inc Files For Offering Of Up To $100M Of Shares Of Common Stock; Says In Addition, Additional $2M Of Shares Of Common Stock Issued As Commitment Shares To Lincoln Park Capital Fund
Benzinga Newsdesk
-
May 3, 2023, 8:48AM
Veru Enters Into Common Stock Purchase Agreement Up To $100M With Lincoln Park Capital Fund At Sole Discretion From Time To Time Over 36-Month Period
Benzinga Newsdesk
-
May 3, 2023, 8:36AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch